Background | Intravenous daratumumab for treatment of patients with multiple myeloma involves a lengthy infusion that affects quality of life, and...
Article of the week
Article of the week: Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN
Myeloma Australia's Medical and Scientific Advisory Group (MSAG)Â presents the article of the week. Lenalidomide, bortezomib, and dexamethasone (RVd)...
Article of the week: Once-versus twice-weekly car fi lzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis
Myeloma Australia's Medical and Scientific Advisory Group (MSAG)Â presents the article of the week. Multiple myeloma (MM) is the third most common...
Article of the week: Managing haematology and oncology patients during the COVID-19 pandemic
Myeloma Australia's Medical and Scientific Advisory Group (MSAG) presents the article of the week. The article from Australia’s National Centre for...
Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives
There is an increasing clinical interest in the measure and achievement of minimal residual disease (MRD) negativity in the bone marrow of Multiple...
Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry
Renal impairment (RI) is a poor prognostic factor in patients with multiple myeloma (MM). Despite improvements in survival with the introduction of...
Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data
Bortezomib in combination with cyclophosphamide and dexamethasone (CyBorD, is a well-established frontline chemotherapy regimen for patients with...
The VCAT study
Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous...
Lenalidomide-related Progressive Multifocal Leukoencephalopathy: A Case Report and Review of Drug-related Cases in Multiple Myeloma
Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease of the central nervous system caused by reactivation of John...
Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing.
The treatment landscape for multiple myeloma has dramatically changed over the past decade with the introduction of several new classes of drugs,...
Toward personalized treatment in multiple myeloma based on molecular characteristics.
To date, the choice of therapy for an individual multiple myeloma patient has been based on clinical factors such as age and comorbidities. The...
Imaging in multiple myeloma: How? When?
Bone disease is the most frequent feature of multiple myeloma (MM) and represents a marker of end-organ damage; it is used to establish the...